MaxCyte Appoints New Chief Medical Officer
Ticker: MXCT · Form: 8-K · Filed: Dec 27, 2024 · CIK: 1287098
Sentiment: neutral
Topics: executive-appointment, personnel, biotech
Related Tickers: MXCT
TL;DR
MaxCyte just hired a new CMO with big pharma experience to push their cell therapy tech.
AI Summary
MaxCyte, Inc. announced on December 22, 2024, the appointment of Dr. David L. Davenport as Chief Medical Officer. Dr. Davenport brings extensive experience in clinical development and medical affairs, previously holding leadership roles at companies like Kite Pharma and Kite, a Gilead Company. His appointment is expected to bolster MaxCyte's efforts in advancing its cell and gene therapy platform.
Why It Matters
The appointment of a new Chief Medical Officer with significant industry experience could signal a strategic push by MaxCyte to accelerate its clinical development pipeline and partnerships in the cell and gene therapy space.
Risk Assessment
Risk Level: low — This filing primarily concerns an executive appointment, which is a standard corporate event with no immediate financial or operational risks disclosed.
Key Players & Entities
- MaxCyte, Inc. (company) — Registrant
- Dr. David L. Davenport (person) — Newly appointed Chief Medical Officer
- Kite Pharma (company) — Previous employer of Dr. Davenport
- Kite, a Gilead Company (company) — Previous employer of Dr. Davenport
FAQ
When was Dr. David L. Davenport's appointment as Chief Medical Officer effective?
The filing reports the earliest event as December 22, 2024, indicating the appointment was effective on or around this date.
What is MaxCyte, Inc.'s primary business?
MaxCyte, Inc. is involved in Services-Commercial Physical & Biological Research, specifically focusing on cell and gene therapy platforms.
What is MaxCyte's state of incorporation?
MaxCyte, Inc. is incorporated in Delaware.
What was Dr. Davenport's role prior to joining MaxCyte?
Dr. Davenport held leadership roles in clinical development and medical affairs at Kite Pharma and Kite, a Gilead Company.
What is the filing date for this 8-K report?
This 8-K report was filed as of December 27, 2024.
Filing Stats: 630 words · 3 min read · ~2 pages · Grade level 11.4 · Accepted 2024-12-27 16:30:20
Key Financial Figures
- $0.01 — ge on which registered Common Stock, $0.01 par value MXCT The Nasdaq Stock Mar
Filing Documents
- mxct-20241222x8k.htm (8-K) — 40KB
- mxct-20241222xex10d1.htm (EX-10.1) — 6KB
- mxct-20241222xex99d1.htm (EX-99.1) — 15KB
- mxct-20241222xex10d1001.jpg (GRAPHIC) — 1KB
- mxct-20241222xex10d1002.jpg (GRAPHIC) — 1KB
- mxct-20241222xex10d1003.jpg (GRAPHIC) — 1KB
- mxct-20241222xex10d1004.jpg (GRAPHIC) — 1KB
- mxct-20241222xex10d1005.jpg (GRAPHIC) — 1KB
- mxct-20241222xex99d1001.jpg (GRAPHIC) — 4KB
- 0001558370-24-016493.txt ( ) — 200KB
- mxct-20241222.xsd (EX-101.SCH) — 3KB
- mxct-20241222_lab.xml (EX-101.LAB) — 16KB
- mxct-20241222_pre.xml (EX-101.PRE) — 10KB
- mxct-20241222x8k_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On December 23, 2024, the Company issued a press release announcing Mr. Mandell's retirement. A copy of the press release is attached hereto as Exhibit 99.1. The information contained in this Current Report on Form 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 10.1 Resignation Letter, dated December 22, 2024 99.1 Press Release, issued December 23, 2024 104 Cover Page Interactive Data (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MaxCyte, Inc. Dated: December 27, 2024 By: /s/ Douglas Swirsky Douglas Swirsky Chief Financial Officer